CAPLIPOINT

New Filing detected. See link for details.

- Transcript of the Q1 FY27 Earnings Call held on August 12, 2026, concerning the financial performance for the quarter ended June 30, 2026, is now available. - The transcript can be accessed on the company's website at https://www.caplinpoint.net/wp-content/uploads/2026/08/Q1-FY-27-Earnings-Conference-Call-Transcript.pdf.

- Audio recording of the Q1 FY2026-27 Earnings Call, held on August 12, 2026, at 16:30 IST, is now available on Caplin Point Laboratories Limited's website.

- Q1 FY27 Consolidated Revenue ₹610.4 Cr vs ₹510.2 Cr (▲19.6% YoY) - EBITDA ₹247.0 Cr vs ₹200.9 Cr (▲23.0% YoY) - PAT ₹179.1 Cr vs ₹150.8 Cr (▲18.8% YoY) - EBITDA Margin 38.4% vs 37.7% (▲70bps) - Recommended a Final Dividend of Rs. 4/- (200%) per equity share for FY26.

- Board of Directors met on August 12, 2026. - Re-appointed Dr. Sridhar Ganesan as Managing Director for 2 years (Aug 25, 2026 - Aug 24, 2028). - Appointed Mr. D. Muralidharan as Whole-Time Director for 2 years (Aug 12, 2026 - Aug 11, 2028), continuing as CFO. - Appointments are subject to shareholder approval.

- Q1 FY27 Consolidated Total Revenue ₹643.9Cr vs ₹533.4Cr (▲20.7% YoY) - EBITDA ₹247.0Cr vs ₹200.9Cr (▲23.0% YoY) - PAT ₹179.1Cr vs ₹150.8Cr (▲18.8% YoY) - EBITDA Margin 38.4% vs 37.7% (▲70bps)

- Board approved 35th Annual General Meeting (AGM) to be held on September 25, 2026. - Record Date set as September 18, 2026, for the AGM and payment of Final Dividend for FY 2025-26.

- Q1 FY27 Consolidated Revenue from Operations ₹610.4Cr vs ₹510.2Cr (▲19.6% YoY) - EBITDA ₹247.0Cr vs ₹200.9Cr (▲23.0% YoY) - PAT ₹179.1Cr vs ₹150.8Cr (▲18.8% YoY) - EBITDA Margin 38.4% vs 37.7% (▲70bps) - Board recommended a Final Dividend of Rs.4/- per equity share (200%) for FY26. - Dr. Sridhar Ganesan re-appointed as Managing Director for 2 years (August 25, 2026 to August 24, 2028). - Mr. D. Muralidharan appointed as Whole-Time Director for 2 years (August 12, 2026 to August 11, 2028), also continuing as CFO. - Company secured emergency tenders of $7M in Central America and $12M in Chile. - Free Cash Reserves at ₹1,502 Cr and Total Liquid Assets at ₹2,875 Cr. - Allocated ₹1000+ Cr enhanced Capex for investment projects, to be financed through internal accruals.

- Concall Schedule - Concall Date: August 12, 2026 - Concall Time: 4:30 PM IST - Purpose: To discuss Q1 FY27 financial performance

- Trading Window for Caplin Point Laboratories Limited will close from July 01, 2026. - The closure is for the finalization of unaudited financial results for the quarter ended June 30, 2026. - The window will reopen 48 hours after the financial results are declared.

Caplin Point Laboratories Limited informed about its participation in the 16th Annual Global Investor Conference titled “TRINITY INDIA 2026”. The meeting will be held on May 28, 2026, Thursday, at 10:00 AM in Mumbai, involving one-to-one and group physical meetings with various analyst/institutional investors. The schedule is subject to changes.

Caplin Point Laboratories Limited announced the availability of the transcript for its Q4 FY2025-26 earnings call, which was held on Thursday, May 14, 2026. The call pertained to the company's financial performance for the quarter and year ended March 31, 2026. The transcript is accessible on the company's website.

New Filing detected. See link for details.

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA final approval for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag). This generic therapeutic equivalent version of Foscavir Injection is used to treat CMV retinitis in AIDS patients and HSV infection. The reference listed drug had US sales of approximately $15 million for the 12-month period ending March 2026.

The Board of Directors of Caplin Point Laboratories Limited, at its meeting on May 14, 2026, declared an Interim Dividend of INR 4.00 (200%) per equity share for the financial year ended March 31, 2026, with May 30, 2026, as the record date. The Board also approved the Audited standalone and consolidated financial results for the year ended March 31, 2026, which received an unmodified opinion from the statutory auditors. Amendments to the Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information were also approved.

New Filing detected. See link for details.

New Filing detected. See link for details.